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Abstract
Background: Hepcidin is a 25-aminoacid cysteine-rich iron regulating peptide. Increased hepcidin concentrations lead to
iron sequestration in macrophages, contributing to the pathogenesis of anaemia of chronic disease whereas decreased
hepcidin is observed in iron deficiency and primary iron overload diseases such as hereditary hemochromatosis. Hepcidin
quantification in human blood or urine may provide further insights for the pathogenesis of disorders of iron homeostasis
and might prove a valuable tool for clinicians for the differential diagnosis of anaemia. This study describes a specific and
non-operator demanding immunoassay for hepcidin quantification in human sera.
Methods and Findings: An ELISA assay was developed for measuring hepcidin serum concentration using a recombinant
hepcidin25-His peptide and a polyclonal antibody against this peptide, which was able to identify native hepcidin. The
ELISA assay had a detection range of 10–1500 mg/L and a detection limit of 5.4 mg/L. The intra- and interassay coefficients of
variance ranged from 8–15% and 5–16%, respectively. Mean linearity and recovery were 101% and 107%, respectively. Mean
hepcidin levels were significantly lower in 7 patients with juvenile hemochromatosis (12.8 mg/L) and 10 patients with iron
deficiency anemia (15.7 mg/L) and higher in 7 patients with Hodgkin lymphoma (116.7 mg/L) compared to 32 age-matched
healthy controls (42.7 mg/L).
Conclusions: We describe a new simple ELISA assay for measuring hepcidin in human serum with sufficient accuracy and
reproducibility.
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Introduction
Hepcidin is a 25-aminoacid cysteine-rich peptide, present in
human serum and urine [1,2]. It is synthesized predominantly by
hepatocytes as an 84-aminoacid precursor protein and its mature
form is released in circulation [3]. Hepcidin acts by binding to
ferroportin(FPN1),theonlyknowncellironexporter[4],inducingits
internalization and subsequent degradation in the cytoplasm [5]. In
systemic level, hepcidin upregulation results in inhibition of iron
absorption from intestinal enterocytes and iron recycling from
macrophages [5,6].Hepcidinexpressionis up-regulatedby iron and
inflammation and down-regulated by anaemia and hypoxia [7].
Studies in humans have highlighted the crucial role of hepcidin
in the regulation of iron homeostasis. Homozygous mutations of
the gene encoding for hepcidin (HAMP) lead to rare cases of
juvenile hemochromatosis [8]. Furthermore, hepcidin in hemoju-
velin (HJV) associated juvenile hemochromatosis is downregulated
[8,9]. Low or relatively low hepcidin levels, for the degree of iron
load, have been also found in patients with TFR2 hemochroma-
tosis and secondary iron overload diseases such as thalassaemia
intermedia, thalasaemia major and chronic hepatitis C [10–12]. In
contrast, increased hepcidin levels have been reported in end-stage
renal disease and inflammation [13,14].
Several methods for hepcidin quantification in human serum
and urine have been reported. There are two antibody-based
techniques, a dotblot assay, which has been used to measure
hepcidin in urine and is considered semi-quantitative [15,16], and
a commercially available ELISA assay measuring serum prohep-
cidin. The diagnostic utility of the latter is controversial, since
prohepcidin represents a processing intermediate rather than a
biologically significant form [17,18].
Lately there has been a growing interest in the development of
quantification techniques based on mass spectrometry (matrix-
assisted laser desorption ionization (MALDI-), surface enhanced
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(SELDI-TOF MS), or liquid chromatography tandem mass
spectrometry (LC-MS/MS)) that show promising results
[8,13,19,20,21,22,23]. However, some of these approaches did
not use internal standard for the quantification of hepcidin and are
considered semi-quantitative and moreover they require special-
ized equipment that are not widely accessible [8]. Therefore, the
development of a facile ELISA assay remains an unmet need and a
potentially valuable tool for research and diagnostic applications,
although the presence of other hepcidin iso-forms in human
samples, such as hepcidin20 and hepcidin22, might be a
limitation. Recently, a competitive ELISA method for quantifica-
tion of hepcidin was published using functional synthetic peptides
[24]. In this study, we sought to develop an alternative ELISA
method for hepcidin quantification in human serum, using a
recombinant functional hepcidin25-His peptide, which offers the
advantage of a functional tagged molecule produced at high yield
and a polyclonal antibody against this peptide, which can identify
native hepcidin.
Results
Production and characterization of a polyclonal antibody
against hepcidin
Recombinant hepcidin25-His was expressed in yeast P. pastoris
and the biological activity of the isolated monomer was tested
according to Koliaraki et al [25]. Recombinant hepcidin25-His
was used for the immunisation of rabbits and the polyclonal
antiserum was extensively purified with affinity chromatography,
as described in Materials and Methods. Western blot analysis
showed that the recombinant hepcidin-25His was detected by the
polyclonal antibody, whereas another peptide of approximately
the same size, bearing a Myc-His tag and produced in the same
way in P. pastoris (namely negative peptide) [25] was not detected
(data not shown).
In order to determine its binding activity against native hepcidin
we first performed immunohistochemistry on paraffin embedded
mouse liver sections. The antibody showed a strong cytoplasmic
staining in hepatocytes that was reduced after preincubation with
hepcidin25-His (Fig. 1A). Furthermore, the specificity of the
antibody against the native peptide in serum was shown by
Western Blot analysis of TCA-precipitated proteins less than
30 kDa from 10 ml of serum. A single band at 3 kDa was detected
(Fig. 1B). This signal was abolished when the polyclonal antibody
was preincubated with the recombinant peptide hepcidin25-His
(data not shown).
Development and characterization of an ELISA assay for
serum hepcidin measurement
The recombinant peptide and the polyclonal antibody against it
were used for the development of an immunological assay for the
quantification of hepcidin in human serum. After determining the
optimal concentration of antigen and antibody according to
Crowther [26], we proceeded to the analytical characterisation of
our ELISA system.
Our competition ELISA produces a typical calibration curve for
the recombinant hepcidin25-His (Fig. 2). The analytical limit of
detection of the ELISA assay, defined as the concentration
corresponding to the mean signal+3 SD of 10 replicates of the zero
calibrator was 5.4 mg/L. The measurement range was 10–
1500 mg/L. For the statistical analysis of the reproducibility,
linearity and recovery of the hepcidin ELISA assay, we used 3
serum samples ranging from low (22 mg/L) to high (150 mg/L)
concentrations chosen from 32 normal sera tested. The intra-assay
Figure 1. Specificity of the polyclonal antibody against native hepcidin. (A) Immunohistochemical staining of liver tissue sections using the
polyclonal antibody against hepcidin25-His (a-Hep25). Secondary anti-rabbit antibody was used as negative control (negative). The specificity of the
polyclonal antibody was verified after reduction of the signal following preincubation with hepcidin25-His. (B) Western blot analysis of serum proteins
less than 30 kDa. 10 ml of serum was filtered through a 30 kDa filter, and the filtrate was precipitated with 25% TCA. Precipitated proteins were
subjected to electrophoresis on a 4–12% Nu-PAGE gel, followed by Western blot using the polyclonal antibody against hepcidin25-His.
doi:10.1371/journal.pone.0004581.g001
Figure 2. Representative calibration curve for recombinant
hepcidin25-His. The range of the assay is 10–1500 mg/L.
doi:10.1371/journal.pone.0004581.g002
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assaying 12 replicates of each sample in a single assay (Table 1).
The inter-assay CVs were 5–16% as evaluated by 7 subsequent
measurements of the test samples (Table 2). Intra- and inter-assay
CV for the standard curve was 2.8% and 8.5%, respectively.
Analytical recovery was studied by adding the calibrator at 7.5, 30
and 75 mg/L in each serum sample and was found to range from
99–115% with a mean recovery index of 107% (Table 3). Mean
linearity was estimated at 101% after measuring 3 serial dilutions
(1:2, 1:4, 1:8) of the 3 serum samples (Table 4).
Clinical evaluation in iron disorders
Inordertodeterminewhetherourassaywasprovidingbiologically
meaningful measurements, we tested serum samples from patients
with anticipated low hepcidin levels (HJV associated juvenile
hemochromatosis and iron deficiency anemia) [4,8,16,27], com-
pared to healthy controls, as well as from patients with anticipated
high hepcidin levels (Hodgkin’s lymphoma with B-symptoms)
[15,28,29,30].
Mean hepcidin concentration was significantly lower in 10
patients with iron deficiency anemia (15.7 mg/L, p,0.010) and 7
patients with juvenile hemochromatosis (12.8 mg/L, p,0.010) and
significantly higher in 7 untreated patients with Hodgkin’s
lymphoma and B-symptoms (116.7 mg/L, p,0.010), compared
to age-matched healthy controls (42.7 mg/L), as shown in Fig. 3.
Hepcidin levels in 32 healthy controls ranged from 13.4 to
133.5 mg/L, and correlated with serum ferritin (Pearson correla-
tion: 0.474, p=0.006) (Fig. 4).
Correlation with a mass-spec method
In order to better evaluate our assay we performed a
comparison with an already established SELDI-TOF-MS method
[22]. We used 6 serum samples, two of each patient category
(control, low and high hepcidin concentrations). The results from
the MS assay are expressed in nM with the use of the equation:
(sample 2789 m/z peak intensity)610 nM/(hepc24 spiked sample
2673 m/z peak intensity– non spiked sample 2673 m/z peak
intensity). Hepcidin values, measured by our ELISA assay were
also converted to nM. Pearson correlation showed a significant
correlation between our assay and the mass-spec method (Pearson
correlation: 0.863, p=0.027) (Fig. 5).
Discussion
The present study describes a new, biologically significant
immunological assay for hepcidin quantification in human serum,
based on the use of a recombinant hepcidin peptide and a
polyclonal antibody. The recombinant hepcidin25-His was
previously produced in P. pastoris, a system that offers the
advantage of soluble expression at high yield and without the
need of any renaturation procedure. The recombinant hepci-
din25-His peptide was produced in a near native conformation
with all 8 cysteines taking part in disulfide bond formation, as
suggested by mass-spectrometry, and was found to be bactericidal
and active in modulating cellular iron homeostasis [25]. The
recombinant peptide was shown to mimic biological activity of
native hepcidin as prior studies illustrated its ability to bind
ferroportin causing its internalisation and promoting an increase in
the levels of the LIP and a decrease in the expression levels of
transferrin receptor 1 in macrophages [25].
Table 1. Intra-assay variation.
N Mean6SD (mg/L) CV%
Serum 1 12 23.2563.6 15.4
Serum 2 12 5765.7 9.94
Serum 3 12 166.6613 7.83
doi:10.1371/journal.pone.0004581.t001
Table 2. Inter-assay variation.
N Mean6SD (mg/L) CV%
Serum 1 7 25.663.9 15.33
Serum 2 7 57.662.5 4.32
Serum 3 7 184.4616.4 8.88
doi:10.1371/journal.pone.0004581.t002
Table 3. Recovery of calibrator added to human serum samples.
Endogenous hepcidin (mg/L) Calibrator added (mg/L) Expected (mg/L) Observed (mg/L) Percent Recovery
a
Serum 1 28.5
7.5 36.02 40.86 113.4
30 58.52 58.35 99.7
75 103.52 119.26 115.2
Serum 2 59.7
7.5 67.2 70.95 105.6
30 89.7 89.05 99.3
75 134.7 153.2 113.75
Serum 3 177
7.5 184.5 189.37 102.6
30 207 205.77 99.4
75 252 283.73 112.6
a(Observed concentration/Expected concentration)6100.
doi:10.1371/journal.pone.0004581.t003
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in human serum are either semi-quantitative [15,16] or measure
the prohormone whose correlation to the levels of hepcidin25
remains controversial [17,18]. Specifically, prohepcidin does not
respond to physiological stimuli, such as inflammation [30] or iron
absorption and it does not correlate to iron parameters or serum
hepcidin [31,32]. As for the mass spectrometry based techniques
[8,13,19,20,21,22,23] although they are continuously being
improved their accessibility is still limited. The development of a
simple immunoassay for hepcidin quantification is expected to
increase availability of analysis of biological specimens in clinical
laboratories, providing information for the role of hepcidin in
health and disease.
To this direction, we produced a polyclonal antibody against the
recombinant peptide, which was also able to recognize native
hepcidin. Specifically, this antibody showed a strong cytoplasmic
staining in hepatocytes and recognized a single band at
approximately 3 kDa in human serum. Both signals were
abolished after preicubation of the antibody with recombinant
hepcidin25-His. Furthermore, the Western blot of human serum
led to the conclusion that the antibody was specific for the mature
hepcidin peptide found in serum, while propeptides were not
detected, as the immature peptide should not normally be secreted
in the serum [3]. However, we cannot still exclude the possibility
of its binding to the truncated 20aa or 22aa form, as with current
immunochemical methods methods it is difficult to detect such a
band. Subsequently, we used this antibody to develop a
competition ELISA for measuring serum hepcidin concentration.
After examining the analytical characteristics of this assay, which
were found satisfactory, we proceeded in determining the clinical
value of it by measuring hepcidin levels in patients with several
iron disorders. We used patients with iron deficiency anemia,
HJV-associated juvenile hemochromatosis and Hodgkin’s lym-
phoma, manifesting B-symptoms and compared them with healthy
Table 4. Dilution linearity of ELISA.
Hepcidin (mg/L) Dilution factor Expected (mg/L) Observed (mg/L) Percent Recovery
a
Serum 1 23.34 1 23.34
2 11.67 11.6 99.4
4 5.83 5.97 102.4
8 2.92 3.05 104.6
Serum 2 57.73 1 57.73
2 28.86 28.45 98.5
4 14.43 13.77 95.4
8 7.22 7.25 100.5
Serum 3 164.76 1 164.76
2 82.38 82.95 100.7
4 41.19 42.67 103.6
8 20.59 21.27 103.3
a(Observed concentration/Expected concentration)6100.
doi:10.1371/journal.pone.0004581.t004
Figure 3. Hepcidin serum concentration in healthy controls
(control), patients with iron deficiency anemia (IDA), juvenile
haemochromatosis (JH) and Hodgkin’s lymphoma (HL). Box
plots show the 25th and 75th percentile with median value for each
group. Minimum and maximum values are also depicted. Significant
difference compared to control is indicated by asterisk (**p,0.010).
doi:10.1371/journal.pone.0004581.g003
Figure 4. Correlation between serum hepcidin and ferritin in
healthy controls. Hepcidin values measured by our ELISA assay
correlate significantly with ferritin levels. Pearson correlation: 0.474
(p=0.006).
doi:10.1371/journal.pone.0004581.g004
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which ranged from 13.5 to 133.5 mg/L, correlated well with
ferritin values. This implies a high association with iron stores,
which is important for the verification of the biological significance
of the assay. In iron deficiency anemia hepcidin is normally
reduced in order to increase iron absorption and recycling [4]. In
juvenile hemochromatosis, mutations in HJV gene have as a result
the decrease of hepcidin expression and the subsequent iron
overload [27]. We found significantly lower hepcidin levels in both
iron deficiency anemia and juvenile hemochromatosis, as
expected. Hodgkin’s lymphoma is clinically characterized by
symptoms resembling those of chronic infectious diseases and
levels of interleukin-6 are high in untreated patients [28]. Since
interleukin-6 directly induces hepcidin expression, high hepcidin
levels were expected, as we found in these patients [15,29,30].
Moreover, in order to better evaluate our results we performed a
comparison between our competition ELISA and a SELDI-TOF-
MS technique, which is well established [22], and found them to
correlate significantly. It is of note that absolute hepcidin values
vary between the two methods, which is probably due to the
different quantification of the two standards. These results allow us
to conclude that this new ELISA system can effectively quantify
hepcidin in human serum.
Recently another competitive ELISA method for quantification
of hepcidin in human fluids was also published, reporting
reproducible measurements in serum and urine [24]. This assay
was performed by using a functional biotinylated synthetic peptide
as a tracer (Intrinsic LifeSciences, La Jolla, CA), and another one
for the construction of the standard curve (Bachem, King of
Prussia, PA). Our method is based on a different principle from the
one described by this recent work and moreover it utilizes a
functional recombinant peptide. The growing interest in this field
and the new or improved methods that have been published
recently render the universal standardization necessary, in order to
gain meaningful results from hepcidin measurements.
In conclusion, we have developed an ELISA assay capable of
measuring hepcidin in human serum samples at a range of 10–
1500 mg/L with acceptable imprecision, linearity, recovery and
specificity. This assay is easy to apply and utilizes a small amount
of unprocessed serum, bypassing time-consuming preanalytical
procedures. A reliable and easy to apply hepcidin quantification
method could prove a valuable tool for diagnostic applications, as
hepcidin levels may be used for the differential diagnosis of several
disorders including iron deficiency, functional iron deficiency in
patients with renal anemia, anemia of chronic disease and iron
overload disorders.
Materials and Methods
Subjects
This study included 32 healthy controls, 7 patients with HJV
associated juvenile heamochromatosis, 10 with iron deficiency
anemia and 7 with Hodgkin’s Lymphoma manifesting B
symptoms. The study was approved by the ethics committees of
the participating institutions. Informed consent was obtained from
all patients and controls and study procedures were conducted in
accordance with to the Declaration of Helsinki.
Expression and purification of recombinant hepcidin25-
His
For the development of the assay, we used the previously
reported recombinant hepcidin25-His in its monomeric form. This
is expressed in yeast P. pastoris and retains the functional and
structural properties of the native form [25]. Briefly, a P. pastoris
clone expressing hepcidin25 with a His-tag at its C-terminal was
grown for 24 h at 30uC and then induced for 3 days by methanol
0.5%, as described in [25]. Culture supernantant was concentrated
and dialysed with the use of a TFF Prep scale Ultrafiltration
system equipped with a 1 kDa filter (Millipore, Bedford, MA). The
concentrate was first purified using Ni
2-NTA metal affinity
chromatography according to the manufacturer’s instructions
(Qiagen, Hilden, Germany) and then by size exclusion chroma-
tography with a Peptide Superdex column (Amersham Bioscienc-
es, Munich, Germany) in order to isolate the monomer.
Immunization procedure
100 mg of the recombinant hepcidin25-His diluted into 0.4 mL
in PBS were mixed with 0.4 mL of Complete Freund’s adjuvant
(Sigma, St. Louis, MO), and injected into New Zealand white
rabbits subcutaneously. Three boosts in Incomplete Freund’s
adjuvant were performed every 4 weeks following the primary
immunization. A sample of pre-immune serum was taken from the
ear vein before the first injection. The test bleeding was carried out
10 days after the last boost immunization from the ear vein. The
serum was tested for antibody activity with ELISA assay (data not
shown).
Purification of the polyclonal antibody
Polyclonal antiserum was extensively purified by affinity
chromatography. Briefly, total IgGs were first precipitated with
33% ammonium sulfate and the IgG fraction was dialyzed against
PBS [33]. The elimination of the His-tag specific antibodies from
the IgG fraction was performed by repeated purifications on a
column with CNBr-activated Sepharose beads (GE Healthcare,
Uppsala, Sweden) coupled with the 66HIS peptide (Covance,
Princeton, NJ), whereas the specific antibodies against hepcidin
were isolated by affinity chromatography with CNBr-activated
Sepharose beads coupled with the hepcidin25-His peptide.
Immunohistochemistry
Liver tissues from normal mice (C57BL/6) were deparaffinized
two times in xylene for 5 min and dehydrated in dilutions of
ethanol (100%, 95%, 70%) for 2 min each. Endogenous
Figure 5. Correlation between serum hepcidin measured by
our ELISA assay and by the SELDI-TOF-MS method. Hepcidin
values of 6 serum samples, measured by the two methods correlate
significantly. Pearson correlation: 0.863 (p=0.027).
doi:10.1371/journal.pone.0004581.g005
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30 min, followed by immersion in tap water for 5 min. Antigen
retrieval was accomplished by immersing and heating the slides in
10 mM citrate buffer, pH 6.0 three times in a microwave, for
5 min each, after which they were allowed to cool to room
temperature for 20 min. The slides were then incubated in
blocking solution (3% FBS, 1%BSA, 0.05% Tween in TBS) for
30 min, followed by incubation with purified primary antibody
(10 mg/ml) at 4uC for 16 h. After that they were then incubated
with secondary anti-rabbit antibody conjugated with HRP (diluted
1:100 in blocking buffer) (DakoCytomation, Carpinteria, CA) for
1 h. Visualization of the stain was accomplished after addition of
3,39 diaminobenzidine substrate (Sigma, St Louis, MO) for 5 min.
The reaction was stopped by washing with tap water and slides
were counterstained with Hematoxylin (Sigma, St Louis, MO) for
1 min. They were then dehydrated in a 70%, 95% and 100%
ethanol series for 2 min each, cleared by immersing in xylene
twice for 5 min each, and mounted in DPX (Sigma, St Louis,
MO). Secondary antibody alone was used as negative control. In
addition, competition experiments were performed by pre-
incubating overnight at 4uC the polyclonal antibody with
hepcidin25His peptide (1 mg/ml).
Western blot analysis
10 ml of serum were diluted three times in PBS and filtered
through a 0.22 mm filter (Millipore, Bedford, MA). After addition
of 10 mm DTT, serum was filtered again through a 30 kDa cut-
off filter devise (Millipore, Bedford, MA) and the filtrate was
precipitated using 25% TCA. The precipitated proteins were
resuspended in loading buffer and subjected to SDS electropho-
resis on a 4–12% NuPAGE Novex Bis/Tris gel (Invitrogen, San
Diego, CA). Western blot was performed using an XCell II blot
module (Invitrogen, San Diego, CA) and a Protran nitrocellulose
membrane (Schleicher & Schuell, Dassel, Germany) with 0.1 mm
pore size. Non-specific sites were blocked with 5% milk in PBS and
the membrane was probed with rabbit anti-hepcidin25His
antibody (0.5 mg/ml in blocking buffer) or rabbit anti-hepcidin25-
His antibody pre-incubated for 1 h at 37uC with hepcidin25His
(50 mg/ml), followed by incubation with anti-rabbit secondary
antibody conjugated with HRP (DakoCytomation, Carpinteria,
CA). Specific signals were detected with a chemiluminescence
assay kit (ECL, Amersham Biosciences, Munich, Germany).
ELISA procedure
96-well microtiter plates (Costar, Corning, NY) were coated
with hepcidin25-His diluted at 0.5 mg/L in PBS, pH 7.4, at 4uC,
for 16 h. Simultaneously, the polyclonal antibody diluted at
0.33 mg/L in 3% BSA in PBS was incubated with an equal
amount of the calibrator or diluted serum (8 mli n2 5ml PBS per
well) for 16 h at 4uC. As calibrator we used hepcidin25-His diluted
in PBS (5, 20, 50, 200, 500 mg/L). Quantification of the
recombinant peptide was performed with a fluorescent quantifi-
cation system (Quant-It, Qubit), according to the manufacturer’s
instructions (Invitrogen, San Diego, CA). Subsequently, the plates
were washed twice with PBS and blocked with 100 ml of 3% BSA
in PBS for 1 h at 37uC. The complexes formed were then added to
the coated wells in quadruplicates and incubated for 1 h at 37uC.
After 10 washes with PBS containing 0.5 ml/L Tween 20, the
plates were incubated with a secondary anti-rabbit antibody
conjugated with HRP (DakoCytomation, Carpinteria, CA) diluted
1:2000 in 3% BSA in PBS for 1 h at room temperature. The plates
were washed as before and visualization of the signal was
accomplished after addition of 3,39,5,59 tetramethylbenzidin
(Pierce, Rockford, IL) for 10 min at room temperature. The
reaction was stopped after the addition of 0.2 N sulphuric acid and
color development was measured photometrically at 450 nm with
a microplate reader (Bio-rad Model 680, Biorad, Hercules, CA).
Construction of the standard curve was performed with Microsoft
Office Excel.
Hepcidin measurements with SELDI-TOF-MS
For the comparison of our assay with an already existing
method 6 serum samples (two from healthy controls, two from
juvenile hemochromatosis and two from Hodgkin’s Lymphoma)
were sent to the Department of clinical chemistry, Radboud
University Nijmegen Medical Centre for measuring with SELDI-
TOF-MS [22]. In short, internal standard (synthetic hepcidin-24,
Peptide Int., Louisville KY) was added to serum before total
hepcidin was isolated from the sample as described [1]. Next,
SELDI-TOF MS was used to quantify hepcidin-25.
Statistical analysis
Statistical analysis was performed using the SPSS software
(version 16.0, SPSS Inc., Chicago, IL). Difference between
hepcidin concentration in controls and different groups of patients
were analyzed by Mann-Whitney U-test. P values ,0.05 were
considered to be statistically significant. Inter- and intra-assay
coefficients of variance were calculated in order to determine the
accuracy of the assay.
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